Florida State University
fsu.eduTotal trials
231
Active
52
Phase 3
1
Total enrollment
34,108
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Hydrocortisone | — | — | — | — | — | 1 | |
| Yohimbine Hydrochloride | — | — | — | — | — | 1 | |
| Cornstarch Placebo 20mg | — | — | — | — | — | 1 | |
| Cornstarch Placebo 54mg | — | — | — | — | — | 1 |
Next readouts
- 2026-09-30
Top conditions
- Obesity17
- Pain13
- Hypertension11
- Chronic Pain10
- Anxiety10
- Healthy9
- Social Anxiety Disorder7
- HIV Infections6
Frequently asked questions about Florida State University
- How many clinical trials does Florida State University have on ClinicalTrials.gov?
- Florida State University is listed as the lead sponsor on 231 clinical trials in ClinicalTrials.gov, 52 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Florida State University's trials are in Phase 3?
- 1 of Florida State University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Florida State University focus on?
- Florida State University's most-studied conditions on ClinicalTrials.gov are Obesity, Pain, Hypertension, Chronic Pain, Anxiety.
- When are Florida State University's next clinical trial readouts?
- Florida State University has 1 upcoming primary-completion readout tracked here; the soonest is “Cannabinoids and Biological Reactivity to Stress”, expected around 2026-09-30.